Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $127,345.42 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 9,038 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the transaction, the chief executive officer now directly owns 495,026 shares of the company’s stock, valued at $6,974,916.34. This represents a 1.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Bicycle Therapeutics Trading Up 1.7 %

Shares of BCYC stock opened at $15.14 on Wednesday. The firm has a fifty day simple moving average of $19.09 and a two-hundred day simple moving average of $21.82. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.60 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period in the previous year, the firm posted ($1.26) earnings per share. The firm’s revenue for the quarter was down 50.0% on a year-over-year basis. On average, equities analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC boosted its position in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock valued at $39,913,000 after buying an additional 300,000 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock valued at $41,887,000 after acquiring an additional 327,089 shares in the last quarter. First Light Asset Management LLC boosted its holdings in Bicycle Therapeutics by 16.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after acquiring an additional 191,717 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Bicycle Therapeutics by 1,438.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Finally, Avoro Capital Advisors LLC purchased a new stake in shares of Bicycle Therapeutics in the second quarter valued at about $14,168,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BCYC has been the subject of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. JMP Securities cut their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Stephens initiated coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. Finally, B. Riley cut their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.